Develops off-the-shelf multimodal biological immunotherapies to induce anti-tumor immune responses for cancer treatment, with lead product candidates in clinical trials for various cancer types. Utilizes genetically modified adenoviruses and herpes simplex virus platforms for its immunotherapies.